home / stock / blte / blte quote
Last: | $38.37 |
---|---|
Change Percent: | 0.58% |
Open: | $39.7 |
Close: | $38.37 |
High: | $39.98 |
Low: | $37.02 |
Volume: | 35,328 |
Last Trade Date Time: | 03/28/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$38.37 | $39.7 | $38.37 | $39.98 | $37.02 | 35,328 | 03-28-2024 |
$39.93 | $43.45 | $39.93 | $43.45 | $39.93 | 78,352 | 03-27-2024 |
$43.48 | $43.64 | $43.48 | $43.75 | $43.02 | 16,374 | 03-26-2024 |
$43.75 | $44.17 | $43.75 | $44.17 | $42.3001 | 41,766 | 03-25-2024 |
$43.95 | $43.26 | $43.95 | $44.15 | $42.4419 | 35,482 | 03-22-2024 |
$43.77 | $44.65 | $43.77 | $44.65 | $42.845 | 36,649 | 03-21-2024 |
$44.11 | $44.75 | $44.11 | $44.85 | $42.7 | 49,252 | 03-20-2024 |
$44.6 | $41.11 | $44.6 | $44.67 | $39.71 | 86,677 | 03-19-2024 |
$40.97 | $37.73 | $40.97 | $40.97 | $37.73 | 38,301 | 03-18-2024 |
$38.47 | $37.14 | $38.47 | $38.95 | $37.14 | 29,473 | 03-15-2024 |
$37.81 | $38.02 | $37.81 | $38.595 | $34.1804 | 145,556 | 03-14-2024 |
$38.02 | $38.01 | $38.02 | $39.14 | $38.01 | 51,929 | 03-13-2024 |
$39.04 | $45.1 | $39.04 | $45.1 | $38.42 | 61,063 | 03-12-2024 |
$44.6 | $45.53 | $44.6 | $45.91 | $44.6 | 53,652 | 03-11-2024 |
$46.05 | $46.1301 | $46.05 | $46.7 | $45.1 | 42,621 | 03-08-2024 |
$46.58 | $46 | $46.58 | $46.64 | $45.56 | 49,384 | 03-07-2024 |
$46.5 | $46.85 | $46.5 | $47.07 | $45.58 | 34,079 | 03-06-2024 |
$46.8 | $46.726 | $46.8 | $47 | $46.21 | 42,813 | 03-05-2024 |
$47.05 | $46.74 | $47.05 | $47.39 | $45.6913 | 39,559 | 03-04-2024 |
$46.52 | $46.49 | $46.52 | $46.7 | $46.1628 | 41,392 | 03-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
Belite Bio Inc Company Name:
BLTE Stock Symbol:
NASDAQ Market:
Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular Degeneration (Dry AMD) Data from a 24-month Phase 2 trial in adolescent STGD1 ...
Koninklijke KPN NV (KKPNF) is expected to report for Q4 2023 ECA Marcellus Trust I Unit (ECTM) is expected to report for Q4 2023 San Juan Basin Royalty Trust (SJT) is expected to report for Q4 2023 Avenir Wellness Solutions Inc (AVRW) is expected to report for Q4 2023 Carmell Corp...
SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its annual ...